

To,

May 31, 2018

Bombay Stock Exchange Limited
1st Floor, Rotunda Building, Dalal
Street, Fort, Mumbai 400 001

Dear Mr. Manoj Sutar,


Ref: Your mail with Ref no. L/SURV/ONL/PV/JD/ 2018-2019 / 39 dated May 31, 2018 on increase in volume.

With reference to the above captioned email received on May 31, 2018, we wish to bring to your notice that the Company has always maintained high standards of continuous and transparent disclosure of all material information as and when there is any such information which may have impact on the share price of the company's listed securities on the exchange, in accordance with applicable laws.

In the immediate past, the Company's ultimate holding Company Merck KGaA has made certain strategic announcements in respect of its global consumer health business (including its operations in India and entering into agreements in relation thereto) and has entered into agreement for sale by Merck group entities of majority equity stake in the Company to Procter & Gamble Overseas India B.V., who in turn has made a public announcement of open offer to acquire upto 26% of the total outstanding capital of the Company. The Board of Directors of the Company has taken the decision, subject to shareholders' approval (which has been sought by way of postal ballot notice dated April 27, 2018), to enter into agreement to transfer its non-consumer health business to Merck group in India and certain other agreements to ensure business continuity. All these announcements and decisions have been disclosed in a timely manner and uniformly to public at large including by way of filings with the stock exchanges.

Thanking you,

For Merck Limited



Vikas Gupta
General Counsel & Company Secretary



Merck Limited

Registered Office
Godrej One, 8th Floor, Pirojshanagar
Eastern Express Highway, Vikhroli East
Mumbai 400079, India.
Phone +91 22 62109000
Fax +91 22 62109999
www.merck.co.in
CIN: L99999MH1967PLC013726